






## PERSONAL INFORMATION

### Curriculum Vitae

#### Alice Laroni



 Genova, Italy  
 +390103538654  +393420429708  
 [Alice.laroni@hsanmartino.it](mailto:Alice.laroni@hsanmartino.it)  
 <https://rubrica.unige.it/personale/U0NOXFph>

Sex F | Date of birth 22/04/1978 | Nationality Italian

## WORK EXPERIENCE

From February 2022- ongoing

### Associate Professor of Neurology

University of Genova, Genova, Italy

Research, teaching  
Neurology, Neuroimmunology

From February 2019 to January  
2022

### Assistant Professor of Neurology

University of Genova, Genova, Italy

▪ Research, teaching  
Neurology, Neuroimmunology

From February 2016 – ongoing

### Neurologist

IRCCS Ospedale Policlinico San Martino

▪ Multiple sclerosis outpatient clinic, Inpatient Neurology  
Neurology, Neuroimmunology

From October 2014 to January  
2019

### Post-doctoral fellow (Ricercatore di tipo A)

University of Genova, Genova, Italy

▪ Research, teaching  
Neurology, Neuroimmunology

2012-2013

### Research fellow

University of Genova, Genova, Italy

▪ Research  
Neurology, Neuroimmunology

2010-2011

### Italian MS Society Research fellow

University of Genova, Genova, Italy

▪ Research  
Neurology, Neuroimmunology

2008-2009

### Post-Doctoral Fellow

Harvard Medical School and Brigham and Women's hospital, Boston, MA, USA

Research  
Neuroimmunology

## EDUCATION AND TRAINING

- Curriculum Vitae**
- 2012-2015 **PhD** EQF8  
 University of Genova, Genova, Italy  
 ▪ Neuroscience, Neuroimmunology
  - 2004-2009 **Neurologist**  
 University of Padova, Padova, Italy  
 ▪ Neurology
  - 1997-2003 **Medical Doctor** EQF7  
 University of Padova, Padova, Italy  
 ▪ Medicine and Surgery
  - 1992-1997 **Maturità Classica** EQF4  
 Liceo Ginnasio Franchetti, Mestre, Italy  
 ▪ Classical humanities including ancient Greek and Latin, Philosophy, History, Physics, Mathematics, Biological Sciences

**PERSONAL SKILLS**

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C2
German	A1	A1	A1	A1	A1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user  
 Common European Framework of Reference for Languages

**Communication skills** Excellent communication skills gained through my experience as medical doctor, researcher and public speaker.

**Organisational / managerial skills** Leadership (currently responsible for a team of 4 people in the neuroimmunology laboratory- two Post-Doc and two Master's students)

**Computer skills** Very good knowledge of Microsoft Windows operating system, Microsoft Office programs, SPSS, FlowJo, FCS Express, GraphPad Prism

Other skills

Driving licence ▪ B

**ADDITIONAL INFORMATION**

**Career breaks** Two maternity leaves

## Publications

1. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.  
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group.  
Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023.  
PMID: 36776853 **Free PMC article.**
2. CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis.  
Schiavetti I, Barcellini L, Lapucci C, Tazza F, Cellerino M, Capello E, Franciotta D, Inglese M, Sormani MP, Uccelli A, Laroni A.  
Mult Scler Relat Disord. 2023 Feb;70:104494. doi: 10.1016/j.msard.2022.104494. Epub 2022 Dec 30.  
PMID: 36603292 **Free PMC article.**
3. Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study.  
Michelis D, Brunetti N, Solaro C, Mancardi GL, Uccelli A, Inglese M, Laroni A.  
Mult Scler Relat Disord. 2023 Jan;69:104464. doi: 10.1016/j.msard.2022.104464. Epub 2022 Dec 9.  
PMID: 36521384 No abstract available.
4. Vaccinations in patients with multiple sclerosis: a real-world, single-center experience.  
Sbragia E, Olobardi D, Novi G, Lapucci C, Cellerino M, Boffa G, Laroni A, Mikulska M, Stocchi L, Inglese M.  
Hum Vaccin Immunother. 2022 Nov 30;18(6):2099171. doi: 10.1080/21645515.2022.2099171. Epub 2022 Jul 21.  
PMID: 35863064 **Free PMC article.**
5. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.  
Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, Pozzilli C, Lanzillo R, Brescia-Morra V, Margoni M, Gallo P, Callari G, Grimaldi L, Lus G, Calabrese M, Simone M, Marfia GA, Rasia S, Cargnelutti D, Comi G, Zaffaroni M; MS Study Group of the Italian Neurological Society.  
Neurol Sci. 2022 Nov;43(11):6415-6423. doi: 10.1007/s10072-022-06211-8. Epub 2022 Jul 4.  
PMID: 35781765
6. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.  
Schiavetti I, Cordioli C, Stromillo ML, Teresa Ferrò M, Laroni A, Cocco E, Cola G, Pasquali L, Rilla MT, Signoriello E, Iodice R, Di Sapio A, Lanzillo R, Caleri F, Annovazzi P, Conte A, Liberatore G, Ruscica F, Docimo R, Bonavita S, Ulivelli M, Cavalla P, Patti F, Ferraro D, Clerico M, Immovilli P, Di Filippo M, Salvetti M, Sormani MP.  
Mult Scler. 2022 Nov;28(13):2106-2111. doi: 10.1177/13524585221102918. Epub 2022 Jun 23.  
PMID: 35735030
7. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.  
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordon V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group.  
Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404.  
PMID: 35607769 **Free PMC article.**
8. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.  
Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, Visconti V, Serrati C, Gandoglia I, Tassinari T, Perego G, Bricchetto G, Gazzola P, Mannironi A, Stromillo ML, Cordioli C, Landi D, Clerico M, Signoriello E, Cocco E, Frau J, Ferrò MT, Di Sapio A, Pasquali L, Ulivelli M, Marinelli F, Pizzomo M, Callari G, Iodice R, Liberatore G, Caleri F, Repice AM, Cordera S, Battaglia MA, Salvetti M, Franciotta D, Uccelli A; CovaXiMS study group.  
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.  
PMID: 35526306 **Free PMC article.**
9. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.  
Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS.  
Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19.  
PMID: 35078125 Clinical Trial.
10. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.  
Palmeri S, Ponzano M, Ivaldi F, Signori A, Lapucci C, Casella V, Ferrò MT, Vigo T, Inglese M, Mancardi GL, Uccelli A, Laroni A.  
CNS Drugs. 2022 Jan;36(1):83-96. doi: 10.1007/s40263-021-00875-0. Epub 2021 Dec 11.  
PMID: 34894339
11. Caregiver Involvement in MS: Duty or Disruption?  
Kesseling J, Boyko A, Laroni A, Bharadia T, van Galen P, Alexandri N.  
Neurol Ther. 2022 Mar;11(1):9-20. doi: 10.1007/s40120-021-00299-4. Epub 2021 Nov 18.  
PMID: 34792783 **Free PMC article.**
12. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.  
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators.  
Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X.  
PMID: 34687636

## Curriculum Vitae

13. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.  
Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Da Rin G, Serrati C, Gandoglia I, Tassinari T, Perego G, Bricchetto G, Gazzola P, Mannironi A, Stromillo ML, Cordioli C, Landi D, Clerico M, Signoriello E, Frau J, Ferrò MT, Di Sapio A, Pasquali L, Ulivelli M, Marinelli F, Callari G, Iodice R, Liberatore G, Caleri F, Repice AM, Cordera S, Battaglia MA, Salvetti M, Franciotta D, Uccelli A; CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS.  
EBioMedicine. 2021 Oct;72:103581. doi: 10.1016/j.ebiom.2021.103581. Epub 2021 Sep 22.  
PMID: 34563483 **Free PMC article.**
14. A real-world study of alemtuzumab in a cohort of Italian patients.  
Russo CV, Saccà F, Frau J, Annovazzi P, Signoriello E, Bonavita S, Grasso R, Clerico M, Cordioli C, Laroni A, Capobianco M, Torri Clerici V, Sartori A, Cavalla P, Maniscalco GT, La Gioia S, Caleri F, Giugno A, Iodice R, Carotenuto A, Cocco E, Fenu G, Zaffaroni M, Baroncini D, Lus G, Gallo A, De Mercanti SF, Lapucci C, Di Francescantonio V, Brambilla L, Sormani MP, Signori A.  
Eur J Neurol. 2022 Jan;29(1):257-266. doi: 10.1111/ene.15121. Epub 2021 Oct 5.  
PMID: 34558755 **Free PMC article.**
15. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.  
Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, Bruschi N, Minguzzi S, Ivaldi F, Poirè I, Laroni A, Mancardi G, Capello E, Uccelli A, Novi G, Inglese M.  
Neurotherapeutics. 2021 Oct;18(4):2579-2588. doi: 10.1007/s13311-021-01104-8. Epub 2021 Sep 22.  
PMID: 34553320 **Free PMC article.**
16. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.  
Di Filippo M, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, Ragonese P, Nociti V, Radaelli M, Laroni A, Buttari F, Loreface L, Ferraro D, Gajofatto A, Prosperini L, Fantozzi R, Boffa L, Lanzillo R, Moccia M, Clerico M, De Luca G, Tomassini V, Calabrese M, Borrelli A, Paolicelli D, Maniscalco GT, Gazzola P, Gallo A, Solaro C, Cocco E, Gasperini C, Tortorella C; RIREMS (Rising Researchers in MS) group.  
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):448-450. doi: 10.1136/jnnp-2021-327200. Epub 2021 Aug 18.  
PMID: 34408003 No abstract available.
17. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?  
Tazza F, Lapucci C, Cellerino M, Boffa G, Novi G, Poire I, Mancuso E, Bruschi N, Sbragia E, Laroni A, Capello E, Inglese M.  
J Neurol Sci. 2021 Aug 15;427:117501. doi: 10.1016/j.jns.2021.117501. Epub 2021 May 20.  
PMID: 34044238 **Free PMC article.**
18. Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups.  
Donninelli G, Studer V, Brambilla L, Zecca C, Peluso D, Laroni A, Michelis D, Mantegazza R, Confalonieri P, Volpe E.  
Front Immunol. 2021 Mar 10;12:633167. doi: 10.3389/fimmu.2021.633167. eCollection 2021.  
PMID: 33777018 **Free PMC article.**
19. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.  
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Loreface L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M.  
J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6.  
PMID: 33770708
20. Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy.  
Godano E, Barra F, Allodi A, Ferraiolo A, Laroni A, Novi G, Mancardi GL, Gustavino C, Arioni C.  
Ital J Pediatr. 2021 Mar 23;47(1):69. doi: 10.1186/s13052-021-01025-4.  
PMID: 33757559 **Free PMC article.**
21. Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.  
Cellius EG, Thompson H, Pontaga M, Langdon D, Laroni A, Potra S, Bharadia T, Yeandle D, Shanahan J, van Galen P, Alexandri N, Kesselring J.  
Patient Prefer Adherence. 2021 Jan 8;15:15-27. doi: 10.2147/PPA.S268829. eCollection 2021.  
PMID: 33447018 **Free PMC article.** Review.
22. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.  
Toboso I, Tejada-Velarde A, Alvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, Sainz de la Maza S, Alvarez-Cermeño JC, Izquierdo G, Paramo D, Oliva P, Casanova B, Agüera-Morales E, Franciotta D, Gastaldi M, Fernández O, Urbaneja P, Garcia-Dominguez JM, Romero F, Laroni A, Uccelli A, Perez-Sempere A, Saiz A, Blanco Y, Galimberti D, Scarpini E, Espejo C, Montalban X, Rasche L, Paul F, González I, Álvarez E, Ramo C, Caminero AB, Aladro Y, Calles C, Eguía P, Belenguer-Benavides A, Ramió-Torrentà L, Quintana E, Martínez-Rodríguez JE, Oterino A, López de Silanes C, Casanova LI, Landete L, Frederiksen J, Bsteh G, Mulero P, Comabella M, Hernández MA, Espiño M, Prieto JM, Pérez D, Otano M, Padilla F, García-Merino JA, Navarro L, Muriel A, Frossard LC, Villar LM.  
Front Neurol. 2020 Dec 17;11:579438. doi: 10.3389/fneur.2020.579438. eCollection 2020.  
PMID: 33408681 **Free PMC article.**
23. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.  
Laroni A, Schiavetti I, Sormani MP, Uccelli A.  
Mult Scler. 2021 Dec;27(14):2126-2136. doi: 10.1177/1352458520971817. Epub 2020 Nov 18.  
PMID: 33205695
24. Magnetic Resonance Imaging Finding of Periodontal and Inferior Alveolar Nerve Inflammation in a Subject With Trigeminal Neuralgia.  
Laroni A, Signorini G, Caserta M, Canevari M.  
Headache. 2020 Nov;60(10):2631-2632. doi: 10.1111/head.14002. Epub 2020 Oct 31.  
PMID: 33128237 No abstract available.
25. Assessing upper limb function in multiple sclerosis using an engineered glove.  
Carmisciano L, Signori A, Pardini M, Novi G, Lapucci C, Nesi L, Gallo E, Laroni A, Cellerino M, Meli R, Sbragia E, Filippi L, Uccelli A, Inglese M, Sormani MP.  
Eur J Neurol. 2020 Dec;27(12):2561-2567. doi: 10.1111/ene.14482. Epub 2020 Sep 9.  
PMID: 32805743

## Curriculum Vitae

26. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.  
Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Perini P, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Pareja-Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Clerici VT, Sartori A, Rasia S, Cordioli C, Stromillo ML, Di Sapio A, Pontecorvo S, Grasso R, Barone S, Barrilà C, Russo CV, Esposito S, Ippolito D, Landi D, Visconti A, Sormani MP. *Neurol Neuroimmunol Neuroinflamm.* 2020 Aug 14;7(6):e878. doi: 10.1212/NXI.0000000000000878. Print 2020 Nov. PMID: 32801167 **Free PMC article.**
27. Tailoring B cell depletion therapy in MS according to memory B cell monitoring.  
Novi G, Bovis F, Fabbri S, Tazza F, Gazzola P, Maietta I, Currò D, Bruschi N, Roccatagliata L, Boffa G, Lapucci C, Pesce G, Cellerino M, Solaro C, Laroni A, Capello E, Mancardi G, Sormani M, Inglese M, Uccelli A. *Neurol Neuroimmunol Neuroinflamm.* 2020 Aug 4;7(5):e845. doi: 10.1212/NXI.0000000000000845. Print 2020 Sep. PMID: 32753406 **Free PMC article.**
28. Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirms group.  
Moccia M, Annovazzi P, Buscarinu MC, Calabrese M, Cavalla P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Loreface L, Mallucchi S, Nociti V, Paolicelli D, Pinardi F, Prosperini L, Radaelli M, Ragonese P, Tomassini V, Tortorella C, Cocco E, Gasperini C, Solaro C. *Mult Scler Relat Disord.* 2020 Oct;45:102394. doi: 10.1016/j.msard.2020.102394. Epub 2020 Jul 12. PMID: 32683308
29. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.  
Boffa G, Lapucci C, Sbragia E, Varaldo R, Raiola AM, Currò D, Roccatagliata L, Capello E, Laroni A, Mikulska M, Gualandi F, Uccelli A, Angelucci E, Mancardi GL, Inglese M. *Eur J Neurol.* 2020 Oct;27(10):2047-2055. doi: 10.1111/ene.14324. Epub 2020 Jun 16. PMID: 32418281
30. CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis.  
Laroni A, Uccelli A. *J Clin Med.* 2020 May 13;9(5):1450. doi: 10.3390/jcm9051450. PMID: 32414131 **Free PMC article.** Review.
31. Informing MS patients on treatment options: a consensus on the process of consent taking.  
Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu MC, Buttari F, Calabrese M, Cavalla P, Cocco E, Cordioli C, De Luca G, Di Filippo M, Fantozzi R, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Fermo SL, Malucchi S, Maniscalco GT, Moccia M, Nociti V, Paolicelli D, Pesci I, Prosperini L, Ragonese P, Tomassini V, Clerici VLAT, Rodegher M, Gherardi M, Gasperini C; RIReMS Group. *Neurol Sci.* 2020 Aug;41(8):2249-2253. doi: 10.1007/s10072-020-04339-z. Epub 2020 Apr 2. PMID: 32240416
32. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.  
Maniscalco GT, Saccà F, Lanzillo R, Annovazzi P, Baroncini D, Binello E, Repice A, Perini P, Clerico M, Mataluni G, Bonavita S, La Gioia S, Gutierrez LP, Laroni A, Frau J, Cocco E, Torri Clerici V, Zarbo IR, Sartori A, Signoriello E, Rasia S, Cordioli C, Stromillo ML, Cerqua R, Pontecorvo S, Di Sapio A, Grasso R, Barone S, Lavorgna L, Barrilà C, Landi D, Russo CV, Frigeni B, Ippolito D, Turano G, Carmisciano L, Sormani MP, Signori A. *Mult Scler Relat Disord.* 2020 Jul;42:102059. doi: 10.1016/j.msard.2020.102059. Epub 2020 Mar 16. PMID: 32208344
33. Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.  
Cellerino M, Ivaldi F, Pardini M, Rotta G, Vila G, Bäcker-Koduah P, Berge T, Laroni A, Lapucci C, Novi G, Boffa G, Sbragia E, Palmeri S, Asseyer S, Høgestøl E, Campi C, Piana M, Inglese M, Paul F, Harbo HF, Villoslada P, Kerlero de Rosbo N, Uccelli A. *Neurol Neuroimmunol Neuroinflamm.* 2020 Mar 5;7(3):e693. doi: 10.1212/NXI.0000000000000693. Print 2020 May. PMID: 32139439 **Free PMC article.**
34. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.  
Vanoli E, Montano N, De Angelis G, Badilini F, Mirabella M, Bonavita S, Patti F, Bianco A, Sparaco M, Chisari C, Laroni A, Frigerio F, Bartezaghi M, Rossi S, Turrini R, Mancardi G. *J Neurol Sci.* 2019 Oct 15;405:116423. doi: 10.1016/j.jns.2019.116423. Epub 2019 Aug 8. PMID: 31520869
35. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?  
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Loreface L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. *Neurotherapeutics.* 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. PMID: 31452081 **Free PMC article.**
36. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.  
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group. *J Neurol.* 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17. PMID: 31209573
37. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.  
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. *Trials.* 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z. PMID: 31072380 **Free PMC article.**
38. Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study.  
Annunziata P, Masi G, Cioni C, Gastaldi M, Marchioni E, D'amico E, Patti F, Laroni A, Mancardi G, Vitetta F, Sola P.

## Curriculum Vitae

- Neurol Sci. 2019 Jul;40(7):1383-1391. doi: 10.1007/s10072-019-03830-6. Epub 2019 Mar 22.  
PMID: 30903415
39. Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.  
Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.  
J Neurol. 2019 Mar;266(3):707-716. doi: 10.1007/s00415-019-09193-4. Epub 2019 Jan 16.  
PMID: 30649617
  40. Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.  
Laroni A.  
Mult Scler. 2019 Apr;25(4):510-512. doi: 10.1177/1352458518800776. Epub 2018 Nov 13.  
PMID: 30421641 No abstract available.
  41. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.  
Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.  
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):261-267. doi: 10.1136/jnnp-2018-319208. Epub 2018 Nov 2.  
PMID: 30389778
  42. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.  
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.  
J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.  
PMID: 30259178
  43. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.  
Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A, Laroni A.  
Mult Scler Relat Disord. 2018 Nov;26:52-54. doi: 10.1016/j.msard.2018.09.006. Epub 2018 Sep 11.  
PMID: 30223229
  44. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.  
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP.  
Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25.  
PMID: 30044207
  45. Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.  
Giordana MT, Cavalla P, Uccelli A, Laroni A, Bandini F, Vercellino M, Mancardi G.  
Mult Scler. 2018 Jul;24(8):1133-1137. doi: 10.1177/1352458518763095. Epub 2018 Apr 30.  
PMID: 29708466
  46. A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study.  
Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.  
J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.  
PMID: 29549468
  47. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.  
Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.  
Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.  
PMID: 29438046
  48. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.  
Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.  
Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.  
PMID: 29438041
  49. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.  
Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.  
Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.  
PMID: 29093064
  50. Teriflunomide treatment reduces B cells in patients with MS.  
Gandoglia I, Ivaldi F, Laroni A, Benvenuto F, Solaro C, Mancardi G, Kerlero de Rosbo N, Uccelli A.  
Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov.  
PMID: 29082295 **Free PMC article.**
  51. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.  
Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M.  
Brain. 2017 Nov 1;140(11):2814-2819. doi: 10.1093/brain/awx250.  
PMID: 29053836

## Curriculum Vitae

52. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.  
Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL.  
Neurology. 2017 May 30;88(22):2115-2122. doi: 10.1212/WNL.0000000000003987. Epub 2017 Apr 28.  
PMID: 28455383
53. Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS.  
Bommarito G, Bellini A, Pardini M, Solaro C, Roccatagliata L, Laroni A, Capello E, Mancardi GL, Uccelli A, Inglese M.  
Mult Scler. 2018 Apr;24(5):623-631. doi: 10.1177/1352458517704077. Epub 2017 Apr 10.  
PMID: 28394195
54. Approved drugs for multiple sclerosis: the challenge of choice.  
Sormani MP, Laroni A.  
Lancet Neurol. 2017 Apr;16(4):252-253. doi: 10.1016/S1474-4422(17)30021-2. Epub 2017 Feb 11.  
PMID: 28209332 No abstract available.
55. Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.  
Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A.  
Front Immunol. 2016 Dec 19;7:606. doi: 10.3389/fimmu.2016.00606. eCollection 2016.  
PMID: 28066417 **Free PMC article.** Review.
56. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.  
Gandoglia I, Ivaldi F, Carrega P, Armentani E, Ferlazzo G, Mancardi G, Kerlero de Rosbo N, Uccelli A, Laroni A.  
Immunol Lett. 2017 Jan;181:109-115. doi: 10.1016/j.imlet.2016.11.015. Epub 2016 Dec 2.  
PMID: 27919749
57. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.  
Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL.  
Neurol Sci. 2017 Jan;38(1):53-59. doi: 10.1007/s10072-016-2701-z. Epub 2016 Oct 18.  
PMID: 27757552 Clinical Trial.
58. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.  
Laroni A, Armentani E, Kerlero de Rosbo N, Ivaldi F, Marcenaro E, Sivori S, Gandhi R, Weiner HL, Moretta A, Mancardi GL, Uccelli A.  
J Autoimmun. 2016 Aug;72:8-18. doi: 10.1016/j.jaut.2016.04.003. Epub 2016 May 4.  
PMID: 27157273
59. Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection.  
Laroni A, de Rosbo NK, Uccelli A.  
Immunol Lett. 2015 Dec;168(2):183-90. doi: 10.1016/j.imlet.2015.08.007. Epub 2015 Aug 18.  
PMID: 26296458 Review.
60. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.  
Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group.  
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9. doi: 10.1136/jnnp-2014-309690. Epub 2015 Feb 25.  
PMID: 25716934
61. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.  
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Drenzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Lufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmstrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibaldi V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.  
Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.  
PMID: 25680984
62. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.  
Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL.  
BMC Neurol. 2014 May 12;14:103. doi: 10.1186/1471-2377-14-103.  
PMID: 24885703 **Free PMC article.**
63. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.  
Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL; EAP Investigators.  
BMC Neurol. 2014 Apr 1;14:65. doi: 10.1186/1471-2377-14-65.  
PMID: 24690227 **Free PMC article.** Clinical Trial.
64. Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.  
Laroni A, Novi G, Kerlero de Rosbo N, Uccelli A.  
J Neuroimmune Pharmacol. 2013 Dec;8(5):1062-76. doi: 10.1007/s11481-013-9456-6. Epub 2013 Apr 12.  
PMID: 23579931 Review.
65. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.  
Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G.  
Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26.  
PMID: 23184503 No abstract available.
66. Mesenchymal stem cells as treatment for MS - progress to date.  
Uccelli A, Laroni A, Freedman MS.  
Mult Scler. 2013 Apr;19(5):515-9. doi: 10.1177/1352458512464686. Epub 2012 Nov 1.

## Curriculum Vitae

- PMID: 23124791 Review.
67. T-cell trafficking in the central nervous system.  
Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B.  
Immunol Rev. 2012 Jul;248(1):216-27. doi: 10.1111/j.1600-065X.2012.01140.x.  
PMID: 22725964 Review.
  68. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.  
Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Vamier OE.  
J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16.  
PMID: 22585413
  69. IL-27 imparts immunoregulatory function to human NK cell subsets.  
Laroni A, Gandhi R, Beynon V, Weiner HL.  
PLoS One. 2011;6(10):e26173. doi: 10.1371/journal.pone.0026173. Epub 2011 Oct 19.  
PMID: 22039443 **Free PMC article.**
  70. Can we kill an extra bird with the same stone?  
Laroni A, Giacosa A, Uccelli A, Mancardi GL.  
Inflamm Bowel Dis. 2011 Sep;17(9):E124-5. doi: 10.1002/ibd.21802. Epub 2011 Jun 24.  
PMID: 21710537 No abstract available.
  71. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.  
Uccelli A, Laroni A, Freedman MS.  
Lancet Neurol. 2011 Jul;10(7):649-56. doi: 10.1016/S1474-4422(11)70121-1.  
PMID: 21683930 Review.
  72. A case of thyroiditis during natalizumab therapy for multiple sclerosis.  
Oddo S, Laroni A, Uccelli A, Giusti M.  
J Endocrinol Invest. 2011 May;34(5):408-9. doi: 10.1007/BF03347466.  
PMID: 21677508 No abstract available.
  73. Neuroprotective features of mesenchymal stem cells.  
Uccelli A, Benvenuto F, Laroni A, Giusti D.  
Best Pract Res Clin Haematol. 2011 Mar;24(1):59-64. doi: 10.1016/j.beha.2011.01.004. Epub 2011 Feb 25.  
PMID: 21396593 Review.
  74. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.  
Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL.  
Neurol Sci. 2011 Feb;32(1):181-2. doi: 10.1007/s10072-010-0427-x. Epub 2010 Nov 5.  
PMID: 21052756
  75. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.  
Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ.  
Nat Immunol. 2010 Sep;11(9):846-53. doi: 10.1038/ni.1915. Epub 2010 Aug 1.  
PMID: 20676092 **Free PMC article.**
  76. Three years of experience: the Italian registry and safety data update.  
Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L.  
Neurol Sci. 2011 Jan;31 Suppl 3:295-7. doi: 10.1007/s10072-010-0356-8.  
PMID: 20644975
  77. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.  
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.  
J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.  
PMID: 20236661 Clinical Trial.
  78. Role of the innate immune system in the pathogenesis of multiple sclerosis.  
Gandhi R, Laroni A, Weiner HL.  
J Neuroimmunol. 2010 Apr 15;221(1-2):7-14. doi: 10.1016/j.jneuroim.2009.10.015.  
PMID: 19931190 **Free PMC article.** Review.
  79. Wernicke's syndrome during parenteral feeding: not an unusual complication.  
Francini-Pesenti F, Brocadello F, Manara R, Santelli L, Laroni A, Caregaro L.  
Nutrition. 2009 Feb;25(2):142-6. doi: 10.1016/j.nut.2008.08.003. Epub 2008 Oct 16.  
PMID: 18929463
  80. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy.  
Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, Tiberio M, Battistin L, Gallo P.  
J Neurol. 2006 May;253(5):636-9. doi: 10.1007/s00415-006-0084-4. Epub 2006 Mar 6.  
PMID: 16502215



### Curriculum Vitae

#### Seminars

- 2021 Scientific director, virtual workshop “What neurologists and oncologists MUST know about COVID-19 vaccines?”, Italy.
- 2017 Scientific director, International workshop: “Innate immune cells: linking infections to autoimmunity”, Italy.
- 2015 Organizing Committee, 44<sup>th</sup> conference Italian Neurology Society, Italy.

#### Honour and Awards

- 2016 I Rita Levi Montalcini research prize by the Italian Multiple Sclerosis Society.
- 2016 Special Award of the Jury-at the Premio Aldo Fasolo 2016, University of Turin (science dissemination) for a video on my research (<https://www.youtube.com/watch?v=m6K3XL7WiU0>).
- 2016: local public prize at the Turin Famelab competition.
- 2015 Best Poster Award, at the Annual Conference of the Italian Neurology Society

### Curriculum Vitae

#### Membership of scientific societies

- 2016 – Member of International Society for Neuroimmunology.
- 2012 – Member of Italian Neurological Society (SIN).
- 2007 – Member of Italian Society of Neuroimmunology (AINI)

Genova,  
20/03/2023

